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Heart valve tissue-guided regeneration aims to offer a functional and viable alternative to current prosthetic replacements. Not
requiring previous cell seeding and conditioning in bioreactors, such exceptional tissue engineering approach is a very fascinating
translational regenerative strategy. After in vivo implantation, decellularized heart valve scaffolds drive their same repopulation by
recipient’s cells for a prospective autologous-like tissue reconstruction, remodeling, and adaptation to the somatic growth of the
patient. With such a viability, tissue-guided regenerated conduits can be delivered as off-the-shelf biodevices and possess all the
potentialities for a long-lasting resolution of the dramatic inconvenience of heart valve diseases, both in children and in the elderly.
A review on preclinical and clinical investigations of this therapeutic concept is provided with evaluation of the issues still to be
well deliberated for an effective and safe in-human application.
1. Introduction
Cardiac diseases (CVD), particularly heart valvulopathies,
dramatically affect the world population representing in
2012 the primary cause of death for 17.5 millions of people.
This number is expected to almost duplicate by 2030; thus,
the World Health Organization is prompting a sustained
programme for effective CVD prevention, management, and
monitoring [1–3].
Characterized by rheumatic, degenerative, or genetic
etiology, heart valve diseases interest both pediatric and adult
patients and at end-stage, they require surgical intervention
of reconstruction of the ventricular outflow tract, as well as
correction of its components to restore the unidirectionality
of blood flow among the heart chambers.
Standard healthcare procedures foresee the implanta-
tion of valve prostheses of either mechanical or biological
composition, for which life-long anticoagulation, inability
to repair/grow, or structural deterioration is considered the
main hindrance for a long-lasting functional treatment in
cardiopathic patients. Among the current valve prostheses,
allogeneic valvulated conduits, commonly named homo-
grafts, represent the most akin replacement to a native
tissue, even if their availability is seriously limited by organ
donation shortage. Despite the high structural and functional
resemblance, valve homografts have been reported to degen-
erate in nearly 15 years, like their animals-derived coun-
terparts submitted to xenoimmunological shielding through
glutaraldehyde treatment. At the basis of heart valve biopros-
thetic degeneration are recipient’s inflammatory and immune
responses directed against allo-/xenogeneic epitopes, as, for
example, the human leukocyte antigens (HLA) II or animal
immunological triggers.
In the search for the effective replacement, a close similar-
ity to the native valve is desirable. Adequate hemodynamic
profile, facilitated diffusion of oxygen and nutrients, tissue
adaptation to somatic growth, and full biocompatibility in
terms of absent inflammatory/immune stimuli and throm-
bogenic power are pursued in the design and manufacturing
processes of the ideal valve substitute [4] by application of
tissue engineering principles. A multidisciplinary strategy
is addressed to the development and creation of viable
surrogate tissues for a prospective replacement of malfunc-
tioning valves. Synthetic or natural scaffolds are engrafted
with differentiated or stem cells and submitted to dynamic
stimulation in bioreactors, conceived to simulate the complex
mechanical and chemical prompts able to generate a physio-
logical tissue/organ maturation [5].
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Synthetic polymers, such as polylactic and polyglycolic
acids (PLA and PGA resp.), have been the first scaffolds
applied for tissue engineered heart valves (TEHVs). Thanks
to the tunable porosity and bioadsorbability, these biopoly-
mers facilitate cell infiltration and likely de novo deposition of
extracellular matrix (ECM) by the same engrafting elements.
Cell type selection for TEHVs has been heterogeneous. From
differentiated cells, as saphenous vein-derived endothelial
and fibroblast cells, to progenitors or less committed ele-
ments, as mesenchymal or endothelial progenitor cells, a
strong propensity for adhesion and/or tissue integration
has been demonstrated [6–8]. Specifically, accurate studies
on heart valve embryonic developmental steps fostered the
implementation of the manufacturing process with cues
essential for a boosted cell differentiation [9–11]. A dynamic
conditioning for at least 14 days was reported to be sufficient
for effective maturation of cell-repopulated synthetic scaf-
folds prior to implantation.
While several technical advancements have been pro-
posed for in vitro formulation and in vivo delivery of such
TEHVs, specific flaws still hamper their clinical applicability.
Inability to reach mature composition, distribution, and
conformation of newly synthesized ECM, in terms of colla-
gen, glycosaminoglycans, and furthermore elastin network,
prevents the achievement of proper hemodynamic func-
tionality in the right circulation system, where these valve
prototypes are usually tested. Improper valve stratification
and cusp thickening provoke incompetent leaflet coaptation
and, hence, regurgitation events, which could be expected to
worsen in conditions of arterial circulation.
Conversely, a natural scaffold has already reached the
state of maturation of its extracellular matrix fibers. After
effective removal of endogenous cellular elements by means
of enzymatic and/or detergents-based decellularization, it can
be implemented as a starter matrix for further colonization
with selected cell types.
Apart from classical TEHVs, a novel valve substitute with
bona fide self-regeneration ability has been advanced, namely,
the tissue-guided regenerated replacement.
This review paper aims to evaluate the evolution steps of
heart valve tissue-guided regeneration from the first bench
experiments to the outcomes of the current bed applications.
2. Which Scaffold? and Which
Decellularizing Manipulation?
The concept of tissue-guided regeneration has been first
introduced with reference to the medical branches of dental
and bone bioengineering, by implying the implantation of
biomimetic scaffolds able to stimulate themselves the regen-
eration process without further factors or biological signals
[12]. In sharp distinction to the classical tissue engineering
conception, it does not contemplate the creation in vitro
or in situ of a living tissue, but the induction of healing
and adaptive remodeling through host’s cell engraftment and
natural physiological conditioning (body as a bioreactor).
Conceived, instead, by many researchers as an exception or
a peculiar modality of tissue engineering, it has been applied
more recently to other medical fields, as in cardiovascular
regenerative medicine.
The combination of cells and synthetic scaffolds has not
be sufficient itself to reproduce the complexity of a vital
and functional 3D tissue. In order to drive effective homing
and instruct cells to proper differentiation and integra-
tion, scaffolds should ideally possess also matrikine signals
and adhesion proteins typical of a healthy native tissue.
Matrikines are classified as extracellular matrix domains able
to interact with specific cell surface molecules belonging to
the large family of cytokines, chemokines, and growth factors.
In concert with adhesion receptors, for example, ligands to
integrins, these proteins significantly influence cell prolifera-
tion,migration, and differentiation [13]. Composition and 3D
spatial distribution of such domains in the starting matrices
are thus fundamental for successful healing processes and
discriminate a biomaterial with self-regenerating abilities
from a scaffold leading to immature or pathological tissue
formation [10, 14, 15].
Full reverse engineering of a native valve tissue ECM by
artificial manufacturing is still a remote prospect. Outflow
tract heart valves are, in fact, highly complex structures with
intrinsic biological and biomechanical properties granting
their opening and closure for virtually 3 billion times during
the entire lifespan [10, 16].
Biological assets, as ECM anisotropy and its depen-
dent cell distribution and specializations, as well as precise
biomechanical characteristics, as specific coaptation height
and minimum leaflet flexion, influence functionality and
durability of native aortic valves.
Natural heart valves have been implanted in replacement
surgery since the 1970s, by adopting animal tissues earlier
submitted to glutaraldehyde treatment for immunologic
shielding and ECM stabilization [17]. With the pioneering
surgical procedure introduced by Ross and colleagues [18,
19], valve homografts entered the full clinical stage, being
applied as replacement of the autologous pulmonary root,
resected and heterotopically implanted in aortic position.
Unfortunately, longevity of these valves in the patients is poor
for mid-/long-term occurrence of structural deteriorations.
Many hypotheses have been advanced in relation to bio-
prosthetic degeneration, as, for instance, the higher mechan-
ical stress introduced by the surgical implantation or the
lack of viable cells induced during glutaraldehyde chemical
treatment or after cryopreservation [20, 21]. In particular, the
cytotoxicity of glutaraldehyde and its free aldehyde groups
provokes in treated cells firstly a suffering state and then their
death with extracellular space release of phosphate groups, as
phospholipids, in the form of the so-called matrix vesicles,
and nucleic acids that act as powerful nucleation sites for
calcification [21]. To improve the stability of glutaraldehyde-
treated tissues, several technical adjustments have been
attempted. Organic solvents, for example, opportune mix-
tures of ethanol, octanediol, and/or octanol, have been
applied during bioprosthetic valve manufacturing to extract
cellmembrane phospholipids, as well as to crosslink collagen-
elastin network [22]. Moreover, detoxification processes have
been introduced to neutralize free aldehyde groups of glu-
taraldehyde. These chemical agents are indeed particularly
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toxic for their ability to interact with primary amino groups
of proteins or nitrogen atoms in DNA, giving rise to Schiff
bases. In addition, they are able to trap plasmatic calcium
further contributing to the triggering or amplification of
calcific events [23, 24]. Amino acids and amino compounds,
that is, glycine, L-glutamic acid, and/or urazole, have been
used as free aldehyde groups neutralizers [24, 25].
Current efforts are posed on the discovery of novel and
less cytotoxic crosslinking agents: as an example, porcine
heart valves treatedwith the natural gardenia fruit compound
genipin were observed conserving a cell viability around 79–
100% with effective induction of tissue stability [26, 27].
Through a different mechanism, cell viability is threat-
ened in cryopreserved allografts by the formation of ice
crystals during the cryocooling phase with induced mechan-
ical stress, intercellular crystallization and thermal shock,
and/or by the cytotoxic effect of osmotic phenomena during
the thawing phase [28]. Controlled settings of temperature
decrease (−1∘C/min) and cryoprotector inclusion (DMSO
or glycerol) are nowadays utilized in tissue banks for the
effective storage of allografts before their clinical need.
Despite the optimizations operated, experimental evi-
dences demonstrate that suchmodifications are not sufficient
for the complete protection of allografts and xenografts from
structural deterioration. A consistent set of data has been
more and more demonstrating that immunological issues
are the triggering factors in the onset of tissue degeneration.
Biochemical and histological analyses on 7 commercially
available animal-derived valve replacements revealed that
only one bioprosthesis, that is, the Epic TM valve from
St. Jude Medicals (St. Paul, MN), has a complete shielding
of alpha-gal xenoantigens. Such xenogeneic epitopes are
oligosaccharides of glycoproteins and glycolipids, displayed
on the surface of vascular endothelial and stromal cells in
all mammals except apes, Old World monkeys, and humans.
An evolutionary gene silencing of the enzyme alpha 1,3-
galactosyltransferase renders these species unable tometabo-
lize alpha-gal [29, 30]. Retrieved at a concentration of at least
107 epitopes per porcine cell, alpha-gal is also expressed by
the human gut bacterial flora, kept under control by the 1%
serum circulating specific IgGs [8, 29–33].
Several studies correlated alpha-gal to the priming of
heart valve calcification through an immune response mech-
anism [34]. The incomplete masking of the epitope could
be exacerbated in vivo by the tissue fatigue, to which the
valve is submitted in the patient’s arterial circulation. The
new crosslinker genipin is per se able to only attenuate the
inflammatory and immune responses to xenogeneic tissues
[26]. Moreover, non-gal xenoantigens have been identified
and no clinical information is yet available regarding their
impact on bioprosthetic graft survival.
The theoretically more biocompatible human valve allo-
grafts fail, however, in a similar time to the xenogeneic coun-
terparts. Again, the main culprit of structural deterioration
is the immune reaction against donor’s antigens [35]. In
particular, the endothelium has been considered to behave as
antigen presenting cell element to the host’s immune system
[36]. The presence of HLA II (or HLA DQ/DR) has been
related to humoral and cellular responses preventing any
accommodation or tolerance of the graft and chronically
inducing its rejection [37, 38].
Amodality to render allo-/xenogeneicmatrices immuno-
privileged and possibly susceptible to further autologous-like
regeneration has been offered by decellularization technol-
ogy. This extraction process has as rational the removal of all
endogenous cell elements, as, for instance, cell membranes,
organelles, and nucleic acids, which can adversely prompt
inflammatory, immune, and calcific events [39, 40].
Several methods for decellularization of organ and tissues
have been formulated, mainly based on osmotic shock,
detergents, and/or enzymes in possible combination with
mechanical agitation and heat to facilitate tissue exposure to
the chemicals.
A treatment with hypotonic or hypertonic solutions or
their alternation, such as low and/or high ionic strength
solutions, can easily induce cell lysis. Hypertonic stress is
severely destructive for several proteins, including those of
the contractile cell machinery, by causing their aggregation
and misfolding in treated tissues and organs [41]. EDTA or
other chelating agents are frequently added in the first decel-
lularization steps to disrupt cell-cell binding and potentiate
the action of the following treatments [42].
Ionic detergents, as sodium dodecyl sulfate (SDS), act
very harshly on protein-protein interactions, while also
solubilizing cell membranes of nuclear type [43]. Nonionic
detergents, such as Triton X-100, show mild solubilization:
theirmain targets are the lipids in interactionwith themselves
or with proteins [44].
Enzymes are usually applied to disrupt cell-cell binding
and proteins. They are eventually used as a terminal step
of the extraction process to remove any trace of nucleic
acids released from lysed cells: such nucleases operate the
hydrolysis of the interior or exterior bonds of ribo- and
deoxyribonucleotide chains, otherwise closely sticking to the
ECM fibers after release in the extracellular space [8].
Most commonly applied procedures relying on SDS
and/or on the trypsin enzyme demonstrated efficacy in
the decellularizing yield but, in turn, revealed inadequate
preservation of the valvular ECM. Elastin fragmentation,
collagen swelling, or, more generally, ECM denaturation and
precipitation were frequently observed. Furthermore, these
chemical treatments affect the glycosaminoglycan moiety of
hyaluronan, cheratins and chondroitin sulfates [14]. As a
result, the tertiary and quaternary structures of associated
ECM macromolecular aggregates are altered and it is desta-
bilized the ability to appease the shocks, provoked by the
enormous pressure variations during the entire cardiac cycle
[45–47].
Among ionic detergents, bile acids and their salt anions
do not cause protein denaturation and, hence, are more con-
servative for treated ECMs. Sodium cholate and deoxycholate
find large application in the decellularization procedures
in combination with either Triton X-100 (TRICOL) [8, 47]
or SDS [48], as well as alone [49]. They differ from SDS
for the rigid steroidal groups in their backbone [43]. Less
frequently, zwitterionic detergents, characterized by mixed
properties of anionic and nonionic surfactants, are applied,
but with several detrimental effects [50]. Biochemical and
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ultrastructural evaluations of most scaffolds decellularized
with bile acids-based treatments revealed good preserva-
tion of collagen and elastin network. Nevertheless, different
results in terms of glycosaminoglycan and basal membrane
integrity were evidenced. Collagen IV, proteoglycans, and
glycosaminoglycans composing the basal laminae are mini-
mally affected by sodium cholate [6, 8, 51], while they can be
damaged and largely removed by sodium deoxycholate [52].
The conservation of the original basal membrane is essential
for further endothelial cell adhesion and for the prevention
of platelet attachment/activation once in vivo.
Zhou and colleagues investigated the effects of different
decellularizing treatments on ECM preservation, as well as
on thrombogenicity and immunogenicity after in vitro direct
contact with human blood.NoECMdisruption and complete
decellularization were observed with sodium deoxycholate.
Among all proposed methods, including also the use of SDS,
trypsin/EDTA, or trypsin-detergent-nuclease, thrombogenic
and immunological responses to sodium deoxycholate-
treated ECMs were surely higher [53]. A confirmation to
these observations was obtained through a quantitative
methodology based on immunoblotting technique: Arai and
Orton demonstrated that a conspicuous amount of soluble
protein antigens were still detectable in bovine pericardium
and porcine heart valves after decellularization with SDS and
sodium deoxycholate [54]. On the contrary, the treatment
with sodium deoxycholate alone for 48 hours revealed reduc-
ing smooth muscle actin to 0.96 ± 0.71%, as well as the total
soluble protein to 6.68 ± 2.0% [52].
3. Preclinical Proof-of-Concept of Heart Valve
Tissue-Guided Regeneration
In the large panorama of in vivo preclinical TEHV testing, the
researchers using decellularized scaffolds as starting matrices
challenged the application of the sole ECMwith respect to its
standard arrangement with cells.
With a technology named SynerGraft (CryoLife, Atlanta,
Georgia), O’Brien et al. were able to manufacture acellular
porcine valve conduits by means of a decellularization treat-
ment based on hypotonic solutions, enzymes for the removal
of nucleic acids, and extensive washout. When implanted in
sheep, the xenografts demonstrated competence for 6months
and, at ex vivo analysis, fibroblast repopulation interested
leaflet stroma [55]. Similar results were obtained in the same
ovine model with human cryopreserved decellularized heart
valves in both aortic and pulmonary orthotopic positions
[56].
The second heart valve tissue-guided regeneration trial
was realized in pulmonary position by Konertz and col-
leagues. By comparison of the standard TEHV proce-
dure to its exception, they implanted allogeneic sodium
deoxycholate-decellularized valves, either nude or previously
cell-seeded, to reconstruct the right ventricle outflow tract
in juvenile sheep animals. The outcomes were surprisingly
in favor to the sole scaffold implantation, as documented
by regenerative processes initiated in the valve allografts at
6 months and by the increase in the annulus diameter in
response to somatic growth, reported at nearly 1-year follow-
up [57, 58].
As a further step towards the clinical stage, this group per-
formed a comparative assessment of cryopreserved allografts
versus decellularized heterografts (pig) in the sheepmodel for
a time interval of 10months. In a simulated Ross intervention
approach, hemodynamic function of xenografts revealed to
be satisfactory. In addition, sheep pulmonary homografts
appeared partially devitalized in some valvular regions, while
the acellular porcine valves (from now on referred with the
proprietary name Matrix P) were free from calcifications
and repopulated by endothelial cells and fibroblasts [59]. In
recent times, aortic valve xenografts decellularized with the
same technology were implanted orthotopically in juvenile
sheep. After 4 months of evaluation in systemic circulation,
no adverse events in terms of hemodynamic and biological
performancewere disclosed [60]. In another preclinical study
in the systemic circulation, porcine aortic valves decellular-
ized with sodium deoxycholate were implanted stented in an
allogeneicmodel. Decellularized valves were well performing
and prone to recellularization without calcified foci, which
were revealed instead for the controls, that is, Carpentier-
Edwards glutaraldehyde-treated commercial bioprostheses
(Edwards Lifesciences, Irvine, CA) [61].
Allogeneic aortic valve conduits were evaluated by Baraki
et al. in an ovine model after decellularization with sodium
deoxycholate and SDS. Implanted in orthotopic position,
such valves were trivially regurgitant and did not exhibit
degeneration or dilatation after 9 months of in vivo follow
up.While fresh native allografts used as control showed signs
of mineralization, deterioration, and advanced insufficiency
already at 3 months, decellularized aortic valves were inter-
ested by minimal calcification and incipient repopulation
[62].
The ability to prevent calcification introduced in heart
valves by decellularizationwas also described byHopkins and
colleagues in an allogeneic sheep model: calcium deposits
were absent from acellular cryopreserved pulmonary valve
allografts, whereas severely concerned their native analogues
[63].
With the rational to test acellular aortic valves as sub-
stitutes for the reconstruction of the right ventricle out-
flow tract, we manufactured porcine valvulated conduits
by applying TRICOL technology. Allogeneic decellularized
valves were implanted in a porcine model for maximum
15 months, revealing a good hemodynamic performance
over time. TRICOL decellularized substitutes exhibited ex
vivo progressive regeneration without signs of degenera-
tion (calcifications, fibrosis, and/or thrombosis) or immune
rejection. Original ECM architecture was well preserved.
Engrafted cell elements displayed native-like features, as
the ability to synthesize novel ECM (collagen and elastin
fibers). Regenerated valves appeared vascularized by newly
formed, mature blood vessels, that is, capillaries and vasa
vasorum, especially in media and adventitia of arterial walls.
Interestingly, hallmarks of reinnervation were documented.
Regenerative processes were also confirmed by the pres-
ence of reparative macrophages, namely, M2 populations, in
higher amount with respect to proinflammatory M1. Stem
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cell elements of embryonic, hematopoietic, neural, and mes-
enchymal lineages populated the regenerated aortic valves in
specific topographic regional localization. Such regeneration
signs further confirm the ability of the decellularized native
ECM to behave as a stem cell niche providing cues for proper
cell differentiation [64].
4. Heart Valve Tissue-Guided Regeneration in
the Clinical Arena
Despite the initial difficulties in the acceptance of this
experimental concept as therapeutic, this is the unique TEHV
modality apart from solely endothelialized scaffolds to have
reached to date translational applicability in heart valve
diseased patients.
CryoLife designed, patented, and distributed two novel
valve bioprostheses with the same SynerGraft decellular-
ization technology based on osmotic shock: 500/700 and
CryoValve biodevices.
After the positive outcomes observed in 6 months with
500/700 SynerGraft porcine valves in a weanling sheep right
ventricular outflow tract reconstructionmodel [55], Simon et
al. implanted these valvular substitutes in 4 pediatric patients.
A catastrophic rapid failure of the xenografts led to 3 deaths
in less than 1 year and a prophylactic valve substitution in the
unique surviving child. At bioptic examination, a strong lym-
phocyte reaction was documented. In the disclosure study,
the causes for such hyperacute and acute rejections were
attributed to the xenogeneic extracellular matrix [65], even
if possible culprits should have been researched in residual
xenoantigens (see Alpha-gal: the nightmare in xenogeneic
valve implantation in Section 5).
The other commercial option by CryoLife, that is, Cry-
oValve, is a decellularized valve allograft. Following the
data provided by the company, CryoValve has been already
implanted in 5.700 patients since 2000 [66]. The biodevice
was first evaluated in a small cohort of 36 individuals,
where adequate functionality and no panel reactive antibody
response were documented after 3 months from surgery [67].
In a comparison to historical controls, 14 pediatric
patients, implanted with CryoValve for reconstruction of
cardiac valve defects, displayed decreased titers of HLA I
and II alloantibodies, when tested at 1, 3, and 12 months
postoperatively [68]. Comparable outcomes were disclosed
by Zehr et al. after aortic orthotopic implantation of the same
cryopreserved decellularized allogeneic valve in 22 adult
patients (range 31–80 years) [69].
A reduced titer of panel reactive antibodies is very advan-
tageous especially for patients awaiting heart transplantation.
In 2005, Sayk et al. described histopathological findings
regarding an explanted pulmonary Cryovalve from a 60-
year-old patient who died for bronchopneumonia. After 5
weeks from implantation, no signs of degeneration could
be appreciated. Indeed, coaptation was optimal without any
leaflet thickening. At microscopic examination, polymor-
phonucleocytes andmacrophages were foundmigrated in the
proximal and distal sutures and involved in the elimination
of nonviable donor myocardium. No progenitor, fibroblast,
or myofibroblast infiltration was observed [70]. Such aspects
conform to the outcomes described by Elkins and colleagues
with reference to the two-phase progression of CryoValve
regeneration in the ovine xenogeneic model [56].
After having received US FDA approval in 2008, Cry-
oValve was adopted inmany cardiosurgical centers rendering
possible trials on noninferiority evaluation with respect to
standard cryopreserved allografts. No postsurgery mortality,
freedom from redo procedures, and lower incidence of severe
regurgitation were valued in this comparison [71, 72].
Espousing both the classical and tissue-guided regen-
eration TEHV conceptions, Dr. Haverich and his research
group started a clinical trialing with human pulmonary valve
allografts, decellularized in 2002 with enzymatic (trypsin)
treatment and from 2009 with sodium deoxycholate/SDS
detergents. In contrast to conventional cryopreserved allo-
grafts and glutaraldehyde-fixed bovine jugular vein valves,
decellularized fresh allogeneic valves (manufactured from
2006 within the company Corlife oHG, Hannover, Germany)
were characterized by improved freedom from explantation,
lower transvalvular gradients, and ability to adaptive growth.
Moreover, immune responses mediated by T lymphocytes
and natural killers were absent during the early-term evalua-
tion of 3.5 years [73–75].
Analogously, Dohmen and colleagues evaluated the func-
tional performance of acellular allogeneic valves, both alone
or submitted to previous seeding with patient’s vascular
cells. From 2003 to 2007, 68 patients underwent Ross
procedure with implantation of a pulmonary decellular-
ized allograft. The patients’ group was subdivided in equal
number and submitted to implantation of either SDS- or
sodium deoxycholate-decellularized pulmonary valves. Ade-
quate valve performance was recorded in a 4-year-long
follow-up with a low mortality rate. A discrete increase of
transvalvular gradients was observed over time for control
allografts and allogeneic valves decellularized with sodium
deoxycholate, while no modification was reported for SDS-
treated ones [76]. An immunological and echocardiographic
evaluation was performed by the same group on sodium
deoxycholate-decellularized allografts by comparison to the
cryopreserved correspondents. A total of 20 patients were
examined at specific frequency from surgery. In particular,
HLA alloantibodies titers and eventually panel reactive anti-
body levels were determined at 5, 10, 30, 90, and 180 days
postoperatively. In patients implanted with cryopreserved
allografts, marked value elevations of HLA I andHLA II were
documented already after 30 post-surgery days. Contrasting
data were reported for decellularized allografts: nearly 60%
of patients displayed no increased values, while for the rest of
them either modest HLA I rise or abnormal panel reaction
antibody levels were documented [77].
In the 2005–2010 lustrum, da Costa et al. implanted
in aortic position 41 allogeneic heart valves decellularized
with SDS. Submitted to arterial circulation, acellular valves
demonstrated patency and low rates of calcification. One
of treated patients underwent reoperation due to incoming
mitral stenosis. During surgery, a small fragment of the
implanted aortic conduit was excised. The histopathologic
analysis of the aortic wall sample revealed intact ECM,
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intimal hyperplasia, and trivial medial repopulation by fibro-
blast-like cells [78].
A clinical trial with allogeneic aortic heart valves treated
with TRICOL technology decellularization is now ongoing.
Apart from valvular allografts, another xenogeneic acel-
lular valve, that is, Matrix P, has been tested in clinical appli-
cations. As aforementioned, Matrix P is a porcine pulmonary
heart valve decellularized through the sodium deoxycholate
treatment. The technology has been developed and tested by
Dohmen and colleagues and is commercially distributed by
Autotissue Ltd. (Berlin, Germany). A variant of the Matrix
P with equine pericardial patch extension, that is, Matrix
P Plus, has been conceived for the surgical cases, where a
distal or proximal patch extension is required. Both valves
were granted with the European CE mark in the 2004-2005
biennium.
Matrix P substituteswere first applied clinically from2002
in 103 patients undergoing to the Ross procedure and sub-
sequent hemodynamic evaluation (transthoracic echocardio-
graphy and eventually multislice computed tomography) at
discharge, 3, 6, and 12months after intervention. Two patients
died after surgery for multiorgan sepsis and one reoperation
was performed for false aneurysm after 10months from inter-
vention. In the explanted xenograft, endothelial cell lining
and stromal engraftment of recipient’s cells were evidenced
without signs of inflammation or immune rejection [79].
From 2006 to 2008 (30.5 months), 61 pediatric and
adult patients were submitted to right ventricle outflow tract
reconstruction with Matrix P or Matrix P Plus. Early mor-
tality, settled at almost 8%, was due to non-xenograft related
causes, while postinterventional valve failure occurred in
4 cases, retreated with the same Matrix P Plus. An addi-
tional valve with adequate hemodynamics was removed
after 1.5 years during reoperation of an unsolved, complex
cardiac defect reconstruction. No degeneration aspects were
observed at macroscopic examination and histological evalu-
ation revealed absence of inflammation but reendothelializa-
tion of leaflets and intimal pulmonary wall. Normal structure
and lack of calcification were documented in the remaining
xenografts for the entire intermediate follow-up by computed
tomography and magnetic resonance [80].
In another study, serum samples were collected from
159 patients who underwent heart valve replacement with
glutaraldehyde-treated bioprostheses (porcine or bovine) or
Matrix P/Matrix P Plus. With reference to preimplantation
values, immunological potential of decellularized xenogeneic
valves was evaluated immediately after surgery and at 9–12
months postoperatively. IgG and IgM titers against porcine
collagen I and alpha-gal were investigated to evaluate possible
immune reactions and identify their triggers in ECM or
cellular elements. No significant alteration was reported
for anticollagen response in all implants. Anti-gal titers
were indeed raised in commercial biological prostheses with
respect to decellularized ones, for which a sole IgM response
was documented [81].
Divergent results were although disclosed after implan-
tation of the same Matrix P valves in other independent
studies [82–86]. According to the outcomes of these clinical
evaluations, freedom from graft dysfunction ranged from 50
to 60% with stenosis and pseudoaneurysm as main failure
signs and inflammatory and fibrotic processes as histopatho-
logical evidences.
The controversial results with SynerGraft and Matrix P
grafts should imposemore caution in the application of xeno-
geneic tissues-derived biodevices in humans. A step back to
the preclinical evaluation in human-likemodels (non-human
primates) is mandatory to verify effective biocompatibility in
xenointeractions.
5. Future Developments
Tissue-guided regeneration concept in heart valve surgery
evolved quite rapidly considering that the first preclinical
experiments were performed around the middle 1990s and
the first-in-human trials were carried out in 2000.
Allogeneic decellularized heart valves can now be consid-
ered as a functional therapeutic replacement option; however,
data about their long-term clinical evaluation are still incom-
plete.
Decellularized valve xenografts have entered the clinical
stage too early after nonrobust preclinical investigation.
Many aspects remain hitherto to ponder for a prospective
considerate clinical suitability of heart valve tissue-guided
regeneration.
5.1. Uncomfortable Leavings of Decellularization Treatments:
Cytotoxicity Issues. In the formulation of the decellulariza-
tion cocktail, particular attention should be addressed to the
biochemical properties of each agent used. More precisely,
change of these features is strictly dependent on variations in
theworkingmicroenvironment (temperature, pH, light, etc.).
Enzymes, applied for disruption of cell-cell interactions
or for digestion of nucleic acids, work in specific regimens of
temperature and ionic strength, and prolonged exposure can
induce serious damages to treated cardiovascular scaffolds
[44].
Detergents exert their activity depending on the critical
micelle concentration (cmc), namely, the minimum concen-
tration for individual molecules to spontaneously cluster and
form micelles. The cmc is influenced by previously cited
microenvironmental conditions, as well as by the presence
of proteins, lipids, and other detergents. High cmc is a
characteristic of bile acids, as sodium cholate and deoxy-
cholate, but also of ionic detergents with low concentration
of counterions.
Membrane proteins are solubilized by detergents through
a mimic of the natural lipid bilayer environment, in which
the same ones are found. An elevated cmc level is particularly
crucial in decellularization technology, since the detergents
can be more easily washed out from the scaffolds. Variations
in the pH and temperature of theworking solution can reduce
detergent solubility and, for instance, cause gelation states,
precipitation, or phase separations [43, 87].
Insoluble detergents remain entrapped among the fibers
of the decellularized ECM. Such condition induces a cyto-
toxic microenvironment preventing further cell colonization
[42, 88].
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5.2. Age of the Donor. Several changes in valvular ECMarchi-
tecture and composition are induced by ageing, as shown
by some elegant works [10, 14]. Such varying ECM and cell
properties should be taken into account for TEHV design,
especially for the approaches relying only on the instructing
abilities of the scaffolds.
It is still unknown whether a decellularization treatment
may induce different effects on a young or adult ECM, but it
is likely that the extraction power could be superior in a still
immature scaffold.
Moreover, considering allogeneic valvular implantation,
the donor’s average age is rising to more than 50 years, the
age in which heart valve pathophysiological alterations are
frequently observed as consequence of hypertension and/or
hypercholesterolemia [89].
5.3. Preclinical Heart Valve Evaluation: The Need for Stan-
dardization. Animal studies are undeniably essential to test
the risk management associated with novel (bio)devices and
prevent therapeutic design errors in patients. Following ISO
5840 standards, in vivo studies for the assessment of a valve
device need to be performed site-specifically in at least 10
animals for a duration of 20 weeks. Two sham animals have
to be included for controls, even if there is no specification,
about which already approved bioprostheses should be used
on this purpose. Hemodynamic, hematochemical and patho-
logical tests must be carried out to evaluate performance and
signs of structural damage, calcification, thromboembolism,
inflammation, and degenerative processes.
ISO regulations do not specify the animal species of
the testing model. So far, preclinical models for heart valve
prosthetic evaluation have included sheep and pig animals.
The ovine model is the most utilized [55–63]. Juvenile sheep
(3–6 months) are excellent models to investigate calcification
propensity. These animals well simulate the human valve
physiology for similar anatomy, annulus size, heart rate, and
relatively slow and limited somatic ingrowth. Conversely,
platelet activity is reduced with respect to humans [90]. In
addition, the juvenile ovine model failed to predict hypera-
cute immune rejection in xenointeractionwith decellularized
porcine valves [55, 65].
Pigs are adequate to assess valve-associated thrombotic
complications: in fact, their platelets show in vitro an equal
activity to human ones [61]. Porcine breedswith lower growth
rate are to be preferred to standard animals in order to
properly simulate a human pediatric being [64, 90].
Other animal models, such as the dog and the non-
human primate, find fewer applications in studies of heart
valve assessment due to socio-ethical limitations associated
with their use for scientific aims. However, it will be pivotal to
evaluate biocompatibility of xenogeneic decellularized valves
in a model closer to the human, such as the non-human
primate.
Apart from hemodynamic studies, most histopatholog-
ical analyses are confined to a modest investigation with
poor identification of engrafting cell elements and their
effective viability and activity in the regenerated tissue. As
an example, smooth muscle actin is frequently adopted as
a marker of smooth muscle but can be expressed also by
activated myofibroblasts: thus, alone, it is not indicative of
bona fide cell differentiation and maturation. Additionally,
extensivemolecular and ultrastructural investigations should
be performed to fully dissect the regeneration process and
clearly distinguish inflammatory and immune responses in
implanted decellularized valves.
5.4. Alpha-Gal: The Nightmare in Xenogeneic Valve Implan-
tation. Most decellularization methods reach an effective
yield in the removal of all endogenous cell components.
However, the extractive power of allo- or xenoantigens
from human or animal valve tissues may vary considerably.
Kasimir et al. suggested in 2005 that the elimination of alpha-
gal xenoantigens could be achieved by adding as a further
step to their sodium deoxycholate/Triton X-100-based decel-
lularization a treatment with the nonionic, nondenaturing
IGEPAL CA-630 detergent. This variation to the standard
protocol was reported to be efficient in the removal of
alpha-gal as proven at the histological level [91]. Recently,
we demonstrated through a proprietary ELISA test based
on a commercially available antibody against alpha-gal that
the epitope amount is only halved in porcine heart valves
submitted to sodium cholate, Triton X-100, and IGEPAL
treatment [92]. Despite the application of a similar decel-
lularization protocol, such different experimental outcomes
are to be ascribed to the methodology applied for alpha-
gal detection, that is, the use of a high affinity isolectin
versus an extremely specific antibody [8]. IGEPAL effects on
extracellular matrix biocompatibility were also investigated
in a rat subdermal model. In contrast with untreated acellular
ECMs, IGEPAL counterparts revealed a high propensity for
neoangiogenesis (unpublished data). For a future clinical
application in humans, such an aspect has to be considered
as pathological.
At the present time, TRICOL method is the sole decellu-
larization technology proven to manufacture valve xenoscaf-
folds completely deprived of alpha-gal [8, 33, 92].
Other immunological modifications are currently tested
to abolish the alpha-gal burden. Transgenic pigs knock-out
for this xenoantigen have been generated: hyperacute rejec-
tion of obtained hearts was prevented in immunosuppressed
baboons for at least 6 months [93]. Additional treatments
with recombinant alpha-1,3 galactosidase obtained from Bac-
teroides thetaiotaomicron demonstrated being effective in the
removal of the xenoantigen from decellularized cardiovascu-
lar scaffolds [94, 95].
While these modifications are likely efficacious, they are
associated with high technical complexity and expensive
costs of production.
As already mentioned, alpha-gal is not the sole xenoanti-
gen in animal-derived tissues, though its role in hyperacute
rejection manifestations is undisputed. Non-gal antibodies
are described as further barrier to xenotransplantation. A
captivating bioengineering hypothesis has been formulated
in recent times by Uri Galili in order to favour an immediate
regeneration and hence avoid rejection mediated by non-
gal antibodies. Nanoparticles loaded with alpha-gal could
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be co-injected in grafting procedures with the rational to
bind anti-gal antibodies and force recruitment of pro-healing
macrophages through the release of complement chemo-
tactic factors, thus accelerating remodelling processes for
a prompted autologous-like tissue formation. Positive pre-
liminary results of this intriguing approach in fibrocartilage
and ischemic myocardium settings have been lately disclosed
[96–98]. Further confirmation and, especially, verification
in other xenotransplantation challenges, such as the same
heart valve xenointeraction, are attended. Potentially, such
a tissue functionalization could be easily introduced in the
manufacturing of decellularized heart valves for guided-
tissue regeneration. A soak in a liquid medium containing
these nanoparticles could be sufficient to allow diffusion
through the collagenous network.
5.5. Increasing Biocompatibility, Bioactivity, and Calcifica-
tion Protection: The Multifunctional Fillers. Biofunctional-
ization by means of hydrogel incorporation represents a
smart modality to introduce regenerative signals or improve
the biomechanical properties in the decellularized scaffold
microenvironment. As suggested by Galili, the incorporation
in hydrogel fillers of alpha-gal nanoparticles could allow for
a homogenous distribution into treated scaffolds [98]. As
space filler, Jeong et al. utilized polyethylene glycol, able to
stabilize protein properties and protect them from degrada-
tion of proteolytic enzymes. This macromolecular substance
demonstrated being superior in preventing calcification to
polyacrylamide [99]. The same group developed a novel
valve bioprosthesis based on a porcine tissue aortic root sub-
mitted to decellularization (SDS, Triton X-100, and sodium
lauryl sarcosinate), 𝛼-galactosidase digestion, space filler
functionalization, glutaraldehyde treatment, ethanol/octanol
organic solvent, and glycine-mediated detoxification [100].
Although this extensively modified xenogeneic prosthesis
demonstrated promising functionality and resistance to cal-
cification both in an in vitro circulation experiment and
in heterotopic (aortic-mitral) implantation in the sheep
model, the utilization of glutaraldehyde excludes any valve
remodeling and/or adaptation to the somatic growth of the
recipient, that is, the key goals of tissue-guided regeneration.
5.6. Tissue Banking: The Need for Effective Procedures of
Disinfection, Sterilization, and Preservation. In order to avoid
the transmission of pathogenic contaminants and be dis-
tributed as sterile biodevices, decellularized valves need to be
submitted to proper disinfection or sterilization methods.
A further advantage of decellularization procedures is
given by the possibility tomanipulate tissues in sterile settings
without modifying the extraction power of the treatment.
Prior to allogeneic implantation, human decellular-
ized scaffolds are currently submitted to similar antibiotic
(/antimycotic) cocktails applied in tissue banks. Careful
analyses should be accomplished to investigate the effects of
residual antibiotics on scaffold repopulation. For instance,
amphotericin B is known to modify cell differentiation in
mononuclear cells, which are often participating in regener-
ative events in vivo [101].
Due to their animal origin, xenografts must be terminally
sterilized before clinical application in order to eliminate
any transmissible agent, such as bacteria, fungi, and species-
specific viruses with human tropism (e.g., porcine endoge-
nous retrovirus). While antibiotic solutions do not introduce
any structural modification in treated valves, procedures of
sterilization by 𝛾 irradiation, electron beam, or microwave
alter significantly collagen, elastin, and othermolecules of the
ECM.
For valve bioprostheses, the guidelines contained in ISO
14160 standards indicate the application of terminal liquid
sterilization (TLS) to ensure complete reset of the bioburden,
that is, sterility assurance level of 10−6. The worst-case
scenario has to be simulated also bymeans of superinfections
to verify the efficacy of the applied TLS. After the sterilization
treatment, valve biodevices must be unmodified in their
hemodynamic and biocompatibility assets. Among the TLS
liquids, glutaraldehyde and formaldehyde find most appli-
cation in the manufacturing of valve prostheses. However,
TLS by means of glutaraldehyde or formaldehyde does not
maintain the bioactivity of treated tissues and it is associated
with cytotoxicity induction as previously reported.
For decellularized allografts and xenografts, novel steril-
ization methodologies should be designed.
In an attempt of sterilization of heart valves, Chen and
Wika patented in 2003 a method for the induction of tissue
drying with glycerol followed by ethylene oxide treatment or
ionizing radiation (Patent file US 6534004 B2). The appli-
cation of non-thermal microwave radiation was reported
by Shamis and colleagues to be less aggressive on ECM
scaffolding but not able to generate complete sterilization
[102]. A sterilant treatment with 22.5 kGy gamma irradiation
provoked, instead, a severe destruction of the fibers of the
ECM [103].
The storage of decellularized heart valves in tissue banks
could render immediate the distribution to the cardiac
surgery units as off-the-shelf replacements. So far, cryop-
reservation has found large use for the preservation of heart
valve allografts but also of their decellularized equivalents.
The suitability of this technique for proper valve storage
is much debated. Synergraft cryopreserved decellularized
allogeneic valves did not show signs of structural damage
upon observationwith transmission electronmicroscopy and
two photon-laser scanning confocal imaging [104]. Simi-
larly, we evidenced that no collagen swelling/shrinkage or
clearly distorted/disrupted elastin fibers could be observed
in TRICOL-decellularized cryopreserved pulmonary valve
leaflets [8]. Schenke-Layland et al. reported conversely the
onset of detrimental effects on ECM fibers after cryopreser-
vation [105] and proposed an alternative treatment, that is,
vitrification, as more conservative for effective preservation.
Vitrification can be achieved by adding formamide and 1,2-
propanediol to the standard cryopreservation method, based
on the cryoprotectant DMSO. Heart valves treated with this
methodology demonstrated good hemodynamic profile in
vivo with respect to standard allografts [106].
Residuals of cryoprotectants, such as DMSO, formamide,
and 1,2-propanediol, may induce an ECM milieu toxic for
engrafting cells.
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5.7. Bioengineering Tools to Improve Recellularization. Differ-
ent from other cardiovascular tissues, heart valves can exert
their hemodynamic function even devitalised or acellular.
In the mid-/long-term, however, remodeling abilities are
required to sustain somatic ingrowth in children or, in gen-
eral, to operate reparative processes. Such tissue competences
may rely only on functional cells.
As also evidenced by Zilla et al. in the context of vascular
graft repopulation [107], regenerative abilities could vary
from species to species, with the human less inherently prone
to a fast resolution in healing events.
Histopathological findings of resected decellularized
valves prove the slower onset of repopulation in humans
with respect to the previously observed animal models
[78–80]. To improve recellularization, biofunctionalization
methodologies are currently explored via nanotechnological
modifications. In particular, coating with DNA aptamers or
antibody-mediated enhanced homing revealed being optimal
routes to drive the repopulation with selected circulating cell
elements [108, 109].
5.8. Socio-Economic Concerns upon Costs and Beneficial
Effects for the Cardiopathic Population. Even if decellularized
allo-/xenogeneic valve replacements are relatively less labor-
intensive with regard to standard tissue-engineered heart
valves, the costs for their purchase are prohibitive for the
healthcare system.
Moreover, the implementation of the manufacturing pro-
cess with further technical innovations (i.e., transgenic alpha-
gal KO pigs, recombinant enzymes, etc.) may drastically
increase the Industrial production expenditures.
Tissue-guided regenerated heart valves risk therefore
being a therapeutic option for few. As observed by Burch et al.
[110], the basin of patients eligible for this valve surgical treat-
ment depends on a close evaluation of risks/benefits. In this
viewpoint, long-term follow-up outcomes will shed definitely
light on the effective superiority ranking of decellularized
valves with respect to common allografts.
5.9. Demand for Specific Guidelines in Decellularized Valve
Risk Assessments for Clinical Applicability Granting. The
rapid evolution of heart valve tissue engineering has not
been accompanied by a similarly fast legislative response.
As previously highlighted in several points of this review,
the regulation for a considerate clinical application of novel
decellularized biodevices is to date incomplete. In the lack for
specific guidelines, such novel bioreplacements are rendered
equivalent to standard bioprostheses, for which, however,
characteristics of viability or support to living cell elements
are not contemplated.
As we already pointed out elsewhere, no regulations are
still available for the clinical application of xeno-derived
biomaterials. Already granted with US FDA approval or
CE marking, many commercial biodevices distributed as
decellularized are actually devitalized and with a strong
xenoantigenic load harmful for treated patients [65, 111].
6. Conclusions
The timesaving and the relative simplicity in the manufactur-
ing of acellular valve scaffolds render this therapeutic concept
easily up scalable in Industrial productions and possibly
available for a population of both diseased infants and adults.
With all the prospects for a life-long durability and abilities
of remodelling and adaptation, tissue-guided regenerated
valvular conduits could drastically reduce the number of
reinterventions and hence the health system costs for heart
valve disease management.
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